About Copanlisib

Copanlisib is a PI3K inhibitor with predominant activity against the alpha and delta isoforms1
  • Copanlisib is an investigational compound undergoing phase III clinical trials for the treatment of patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL)
  • Copanlisib is being investigated for uses that are not approved by the FDA, the EMA or other health authorities
  • Copanlisib is a reversible PI3K inhibitor with preferential activity against both p110-α and p110-δ isoforms, compared with p110-beta (β) and p110-gamma (γ)1
  • Copanlisib inhibits the catalytic activity of the class I PI3K-α, -β, -γ, and –δ isoforms with IC50 values of 0.5, 3.7, 6.4, and 0.7 nmol/L, respectively1
Liu N, et al. Mol Cancer Ther. 2013:12(11): 2319-2330.
Reference:

1. Liu N, Rowley BR, Bull CO, et al. Mol Cancer Ther.
2013;12(11):2319-2330.